

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

Claim 1 (currently amended): A combination which comprises (a) 4-[ $\alpha$ -(4-cyanophenyl)-1-(1,2,4-triazolyl)methyl]-benzonitrile (letrozole) or a pharmaceutically acceptable salt thereof and (b) 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmaceutically acceptable salt thereof in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt, for simultaneous, concurrent, separate or sequential use in the prevention reducing of bone loss ~~which is~~ caused by the treatment with an aromatase inhibitor of a disease or condition which responds to aromatase inhibition.

Claims 2-9 (cancelled)

Claim 10 (currently amended): A package comprising a 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmaceutically acceptable salt thereof together with instructions for use in combination with 4-[ $\alpha$ -(4-cyanophenyl)-1-(1,2,4-triazolyl)methyl]-benzonitrile (letrozole) or a pharmaceutically acceptable salt thereof for prevention reducing of bone loss ~~which is~~ caused by the treatment with an aromatase inhibitor of a disease or condition which responds to aromatase inhibition.

Claims 11-17 (cancelled)

Claim 18 (previously presented): A method of treating bone loss in a patient suffering from an estrogen dependent disorder and receiving an aromatase inhibitor comprising administering to said patient an effective amount of a 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmaceutically acceptable salt thereof.

Claim 19 (previously presented): A method of treating cancer treatment-related bone loss in a postmenopausal woman with ER+ and/or PR+ breast cancer receiving an aromatase inhibitor as adjuvant therapy comprising administering to said postmenopausal woman an effective amount of a 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmaceutically acceptable salt thereof.

Claims 20-21 (cancelled)

Claim 22 (previously presented): The method according to claim 18 wherein the aromatase inhibitor is letrozole or a pharmaceutically acceptable salt thereof.

Claim 23 (previously presented): The method according to claim 18 wherein the 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmaceutically acceptable salt thereof is administered once every six months.

Claim 24 (previously presented): A method of treating bone loss caused by the treatment with an aromatase inhibitor of a disease or condition which responds to aromatase inhibition comprising administering to a patient in need of such treatment an effective amount of 4-[ $\alpha$ -(4-cyanophenyl)-1-(1,2,4-triazolyl)methyl]-benzonitrile (letrozole) or a pharmaceutically acceptable salt thereof and an effective amount of a 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmaceutically acceptable salt thereof.

Claim 25 (cancelled)